FIELD: biotechnology.
SUBSTANCE: invention relates to a chimeric antigen receptor (CAR) molecule which recognizes CLDN6, a kit containing it, as well as a nucleic acid which codes it. Also disclosed is a vector, a cell and a population of cells containing said nucleic acid.
EFFECT: invention is effective for treating a disease associated with expression of CLDN6, as well as for stimulating a cell-mediated immune response to a CLDN6 expressing target cell population or tissue in a subject.
51 cl, 10 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| SIGNAL SYSTEM | 2015 |
|
RU2731638C2 |
